Sign Up Today and Learn More About Cour Pharmaceuticals Development Stock
Invest in or calculate the value of your shares in Cour Pharmaceuticals Development or other pre-IPO companies through EquityZen's platform.
Cour Pharmaceuticals Development Stock
Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.
About Cour Pharmaceuticals Development Stock
Founded
2015
Headquarters
Skokie, IL, US
Industries
Apps, Artificial Intelligence, Software
Cour Pharmaceuticals Development Press Mentions
Stay in the know about the latest news on Cour Pharmaceuticals Development
COUR Pharma raises $50 million for type 1 diabetes push
thepharmaletter • Jun 20, 2026
COUR Pharma Announces Closing of $50 Million Series B
biospace • Jun 19, 2026
COUR Pharma Announces Closing of $50 Million Series B
globenewswire • Jun 18, 2026
COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
biospace • Mar 03, 2026
COUR Pharma Publishes Peer-Reviewed Data in Science Advances
biospace • Jan 30, 2026
Cour Pharmaceuticals Development Management
Leadership team at Cour Pharmaceuticals Development
Founder, President and Chief Executive Officer
John J. Puisis
Board of Directors
Simon Greenwood
Join now and verify your accreditation status to gain access to:
- Cour Pharmaceuticals Development Current Valuation
- Cour Pharmaceuticals Development Stock Price
- Cour Pharmaceuticals Development Management
- Available deals in Cour Pharmaceuticals Development and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Cour Pharmaceuticals Development Cap Table and Funding History by Share Class and Liquidity Preferences
- Cour Pharmaceuticals Development Revenue and Financials
- Cour Pharmaceuticals Development Highlights
- Cour Pharmaceuticals Development Business Model
- Cour Pharmaceuticals Development Risk Factors
- Cour Pharmaceuticals Development Research Report from SACRA Research
Trading Cour Pharmaceuticals Development Stock
How to invest in Cour Pharmaceuticals Development stock?
Accredited investors can buy pre-IPO stock in companies like Cour Pharmaceuticals Development through EquityZen funds. These investments are made available by existing Cour Pharmaceuticals Development shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Cour Pharmaceuticals Development stock?
Shareholders can sell their Cour Pharmaceuticals Development stock through EquityZen's private company marketplace. EquityZen's network includes over 460K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 54K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."